“While the phase 3 results of GCAptAIN did not replicate the positive outcomes observed in the phase 2 trial, we remain committed to continuing to drive scientific progress and deepening the ...

"Novartis’ Cosentyx shows no benefit in Phase III GCA trial" was originally created and published by Clinical Trials Arena, a ...

Novartis' blockbuster immunology drug Cosentyx has disappointed in a phase 3 trial involving patients with giant cell ...

Novartis NVS announced that a late-stage study of its interleukin-17A inhibitor, Cosentyx (secukinumab), has failed to meet ...

Novartis announced top-line results from the phase III GCAptAIN study evaluating Cosentyx (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the study, Cosentyx ...

Both regulatory-approved and pipeline treatments for moderate to severe hidradenitis suppurativa demonstrate comparable ...

BOSTON — The human monoclonal antibody secukinumab (Novartis), which selectively neutralizes interleukin (IL)-17A, is safe and effective for patients with ankylosing spondylitis and psoriatic ...

Basel, November 15, 2014 - Novartis announced today results from the MEASURE 1 and MEASURE 2 pivotal Phase III studies of AIN457 (secukinumab) in ankylosing spondylitis (AS).In the studies ...

SAN DIEGO — An intravenous formulation of secukinumab met all primary efficacy endpoints, with an attractive safety profile, in patients with axial spondyloarthritis over 52 weeks, according to ...

Secukinumab, an anti-IL-17A monoclonal antibody biologic drug, showed promise as a treatment for patients with active ankylosing spondylitis, according to new research. Ankylosing spondylitis, or ...

Both secukinumab 300 mg (28.2%) and 150 mg (24.3%) also led to higher ACR50 response rates at week 16 compared with placebo (5.8%), both with significant ORs.

Overview of the clinical trials . 3.1 The company did a systematic review of the literature to identify studies evaluating the clinical effectiveness and safety of secukinumab for treating people with ...